MUTATIONAL PROFILE IN PATIENTS WITH LOW-RISK MYELODYSPLASTIC SYNDROME AT THE TIME OF PROGRESSION TO ACUTE LEUKEMIA

被引：0
|
作者：
Pedrote, B. [1 ]
Falantes, J. F. [1 ]
Carrillo, E. [1 ]
Calderon-Cabrera, C. [1 ]
Espigado, I [1 ]
Perez-Simon, J. A. [1 ]
机构：
[1] Hosp Univ Virgen Rocio, Seville, Spain
来源：
HAEMATOLOGICA | 2019年 / 104卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PC-051
引用
收藏
页码：182 / 182
页数：1
相关论文
共 50 条
  • [41] SWITCHING TO AN ALTERNATIVE RECOMBINANT ERYTHROPOIETIN AGENT MAY BE EFFECTIVE IN PATIENTS WITH LOW-RISK MYELODYSPLASTIC SYNDROME
    Fattizzo, B.
    Rizzo, L.
    Giannotta, J. A.
    Cecchi, N.
    Mazzon, F.
    Barcellini, W.
    Riva, M.
    HAEMATOLOGICA, 2021, 106 (10) : 173 - 173
  • [42] Treatment of myelodysplastic syndrome (MDS) with cytokine immunotherapy for low-risk MDS
    Kadia, Tapan M.
    Kantadian, Hagop
    Verstovsek, Srdan
    Newman, Beth
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    BLOOD, 2007, 110 (11) : 438A - 438A
  • [43] New aspects of the treatment of patients with low-risk myelodysplastic syndromes
    Hofmann, WK
    Seipelt, G
    Kalina, U
    Hoelzer, D
    ONKOLOGIE, 2000, 23 (01): : 12 - 16
  • [44] CORRELATIONS BETWEEN IMMUNOLOGICAL AND MUTATIONAL PROFILE IN MYELODYSPLASTIC SYNDROME
    Cristiano, A.
    Belardi, R.
    Hajrullaj, H.
    Gurnari, C.
    Falconi, G.
    Galossi, E.
    Fenu, S.
    Attardi, E.
    Fabiani, E.
    Voso, M. T.
    Nuccetelli, M.
    LEUKEMIA RESEARCH, 2023, 128
  • [45] Treatment of low-risk myelodysplastic syndromes
    Santini, Valeria
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2016, : 462 - 469
  • [46] Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome
    Tambaro, F. P.
    Garcia-Manero, G.
    O'Brien, S. M.
    Faderl, S. H.
    Ferrajoli, A.
    Burger, J. A.
    Pierce, S.
    Wang, X.
    Do, K-A
    Kantarjian, H. M.
    Keating, M. J.
    Wierda, W. G.
    LEUKEMIA, 2016, 30 (02) : 325 - 330
  • [47] Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome
    F P Tambaro
    G Garcia-Manero
    S M O'Brien
    S H Faderl
    A Ferrajoli
    J A Burger
    S Pierce
    X Wang
    K-A Do
    H M Kantarjian
    M J Keating
    W G Wierda
    Leukemia, 2016, 30 : 325 - 330
  • [48] Risk of myelodysplastic syndrome and acute myeloid leukemia in congenital neutropenias
    Freedman, MH
    Alter, BP
    SEMINARS IN HEMATOLOGY, 2002, 39 (02) : 128 - 133
  • [49] Clinical Characteristics and Mutational Profile of Patients With Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.
    Villarreal, Patricia
    Castro, Maria
    Asinari, Mariana
    Ricchi, Brenda
    Jauk, Federico
    Perusini, Agustina
    Arbelbide, Jorge
    Basquiera, Ana
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S307 - S307
  • [50] Outcome of Patients With Low-Risk and Intermediate-1-Risk Myelodysplastic Syndrome After Hypomethylating Agent Failure
    Jabbour, Elias J.
    Garcia-Manero, Guillermo
    Strati, Paolo
    Mishra, Asmita
    Al Ali, Najla H.
    Padron, Eric
    Lancet, Jeffrey
    Kadia, Tapan
    Daver, Naval
    O'Brien, Susan
    Steensma, David P.
    Sekeres, Mikkael A.
    Gore, Steven D.
    Dezern, Amy
    Roboz, Gail J.
    List, Alan F.
    Kantarjian, Hagop M.
    Komrokji, Rami S.
    CANCER, 2015, 121 (06) : 876 - 882
12345